openPR Logo
Press release

Antibacterial Treatments that don’t Rely on Antibiotics Winding their way through Clinical Development

03-07-2019 12:46 PM CET | Health & Medicine

Press release from: Greystone Research Associates

(Amherst, NH) – As bacteria grow resistant to conventional antibiotics, alternatives are being investigated, including antibodies, probiotics, bacteriophages, and antimicrobial peptides. The quest to replace the current generation of antibiotics is complicated by the methods that bacteria have acquired to evade attempts to destroy them – methods often referred to a virulence factors.

A microorganism can possess a wide array of virulence factors. They may only express these virulence factors when in the presence of certain other microorganisms, or in a particular environment, such as a highly inflamed one. The virulence factor database (VFDB) is an integrated and comprehensive online resource for curating information about virulence factors of bacterial pathogens. Since its inception in 2004, VFDB has been dedicated to providing up-to-date knowledge of VFs from various medically significant bacterial pathogens.

A number of substance classes are being explored to identify those that will successfully treat bacterial infections.The specificity of antibodies, and the inability of bacteria to develop resistance against them, make antibodies attractive, albeit expensive, alternative therapeutic agents. Bacteriophages have been used for therapy in some parts of the world.

Antimicrobial peptides have long been considered as potential replacements for antibiotics but with limited success. Synthetic peptides and synthetic Antibiotic membrane-active agents might herald a shift. Phages are very selective in targeting bacteria: often they are specific at the strain level. This gives the use of phages for therapy two advantages: it does not affect mammalian cells and it does not create dysbiosis because the commensal bacteria are not targeted either. Taken together this will diminish the likelihood of adverse effects.

Phage lysins are enzymes used by bacteriophages to destroy the cell wall of a target bacterium and are potential replacements for antibiotics because of their direct antibacterial action, and as adjuncts because they act to reduce bacterial burden, weaken biofilms, or both.

Wild-type bacteriophages that infect and kill bacteria have the potential to replace antibiotics for some indications. Bacteriophage could be used in small doses because they replicate when their host bacterium is present. During treatment of an infection they might also evolve to infect the strains causing the disease. This replication and evolution makes them unique in pharmaceutical product development.

These developments are detailed in a new and comprehensive report researched and written by Greystone Research Associates. The report – The Global Market for Non-antibiotic Bacterial Therapeutics - analyzes products and candidates in numerous drug classes that have demonstrated efficacy in treating resistant strains of bacteria. The report allows readers to evaluate the current status of treatments designed to ease the burden of decreasingly effective treatments and address the antibiotic resistance problem. It includes analysis of treatment grouping by developer, indication, and drug class, forecasts and profiles.

More information is available at http://www.greystoneassociates.org

About Greystone

Greystone Research Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

Contact:

Mark Smith
Voice: 603-595-4340
www.greystoneassociates.org

Source: Greystone Research Associates

About Greystone

Greystone Research Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

Contact:

Mark Smith
Greystone Research Associates
98 Route 101A
Amherst, NH 03031 USA
Voice: 603-595-4340

www.greystoneassociates.org

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Antibacterial Treatments that don’t Rely on Antibiotics Winding their way through Clinical Development here

News-ID: 1637585 • Views: 233

More Releases from Greystone Research Associates

Seeking to Capitalize on New Device Technology Drug Companies are Reformulating …
(Amherst, NH) – As the pace of competition increases within the pharmaceutical and biotech industries, the concept of life cycle management is becoming a key component of drug product management. Much of the recent emphasis in this area has centered on efforts to extend patent rights protection. While reformulation has been and is an important approach, efforts to prolong IP benefits have only recently involved IV-to-SC drug re-engineering. This migration
3D Printing Positioned to Address Issues that have Prevented Wide Adoption of Mi …
(Amherst, NH) – The promise of commercial microneedle drug delivery has been on the horizon for more than a decade. Like other compelling medical device innovations such as noninvasive glucose monitoring, the potential of the technology has yet to be realized due to the inability to solve the issues of reliable product performance from unit to unit and across a wide user population. To fully address the unmet need these technologies
Analysis of the Oncology Drug Pipeline Reveals Evolving Therapy Correlations and …
(Amherst, NH) – The almost two thousand active oncology clinical trials paint a picture of an evolving therapeutic sector that has established players moving quickly to realize the expanded benefits of recent treatment protocols. A dozen targeted treatments, using novel pathways and signaling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. There approaches have attracted a growing number of drug developers anxious to profit from
For Injectable Drugs Wireless Connectivity Allows Caregivers to Manage Patients …
(Amherst, NH) – The growing emphasis on drug self-administration is having a major impact on the pharmaceutical industry. The aging population and managed care initiatives are major forces driving the growth of home healthcare, a trend that includes the self-administration of drug therapies for chronic conditions such as diabetes, arthritis and hormone replacement therapy. This trend is creating an increased demand for medical devices that are patient-friendly and cost-effective. Much

All 5 Releases


More Releases for Mark

Impressionist landscape artist - Mark Briscoe
I am Mark Briscoe, Bristish artist well established in the field of Chinoiserie furniture decoration and restoration of antique lacquer. But the techniques for fine art easel painting in the wonderful manner of the old masters is something which I have been exploring in great earnest over the last two years as a long cherished desire. And while I cannot claim to have come anywhere near their heights, I have
Intellias Reaches 1000-Employee Mark
On June 4, 2018, Intellias welcomed its 1000th employee. The company is proud to reach such a high bar and sees this number as a new starting point to reaching 2000 people onboard and landing in the top 10 Ukrainian IT companies by headcount. As of today, Intellias has three development centers in Lviv, Kyiv, and Odessa as well as a representative office in Berlin. The 1000th employee will join
Mark de Clive-Lowe
On Thursday, May 3rd, 2012 internationally known musician Mark de Clive-Lowe (MdCL), will take the stage at The Beehive, located in Boston, MA, for a special performance of his revolutionary sound. Be there from 9:30PM to 1:00AM as MdCL plays impromptu remixes created from scratch, on the spot using drum machines, keyboards and special effects. He will start with a jazz-oriented set and crank up the intensity with his signature
Trade Mark Act
Neoinfo Solutions Pvt. LTD is an IT based company with its main office located in Jaipur(rajasthan). Our expertise lies in the domain of Website Designing development portal development,maintenance software consulting, designing development , implimentation, training and maitenance.In the journey of achieving our combined business and social goals we have kept in mind and have always strictly followed all our data security policies to ensure that all informations of our clients
Trade mark Act
Neoinfo Solutions Pvt. LTD is an IT based company with its main office located in Jaipur(rajasthan). Our expertise lies in the domain of Website Designing development portal development,maintenance software consulting, designing development , implimentation, training and maitenance.In the journey of achieving our combined business and social goals we have kept in mind and have always strictly followed all our data security policies to ensure that all informations of our clients
Facebook Dumps Mark Zuckerberg
INDIANAPOLIS—Facebook pulled the plug on Indiana bankruptcy attorney Mark Zuckerberg’s internet Facebook account on Monday, citing false identity as the reason. Obviously, Indianapolis attorney Mark S. Zuckerberg has the same name as Facebook founder Mark S. Zuckerberg, but you would expect Facebook, the internet social-media giant, to have the capability to accommodate two or more people with the same names. Attorney Mark Zuckerberg said, “I was originally denied an account with